GSTM1 and alpha thalassemia spectrum: The amount of Hb Barts detected, which can be quantified on screening (although not necessarily reported to clinicians) and confirmatory testing, can differentiate between a clinically significant condition, requiring ongoing monitoring and treatment (e.g., Hb H disease [−−/α−]) and the alpha-thalassemia silent carrier or trait states.